Agilent Technologies to Acquire Digital Pathology Firm

The $270 million deal integrates software into lab hardware, potentially altering diagnostic workflows for your facility.

Updated on Oct. 26, 2026 in Healthcare

Isometric editorial illustration of laboratory glass slides on a platform, representing the digital integration of pathology diagnostic software. — Agilent Technologies agreed to acquire Proscia for $270 million, integrating the software-driven pathology firm into its laboratory diagnostics business by 2027. AI Illustration. Upload story photo >

Live Poll

Do you believe large corporate acquisitions of specialized software firms generally improve service outcomes for users?

Agilent Technologies has entered an agreement to acquire digital pathology firm Proscia for up to $270 million in an all-cash transaction. The deal, expected to close in early fiscal 2027, integrates Proscia’s software-driven diagnostics into Agilent’s existing laboratory instruments and reagent offerings.

Why it matters

The acquisition allows Agilent to capture a larger share of the pathology market by pairing its physical diagnostic hardware with Proscia's established software platform for tissue analysis. This consolidation reflects a broader trend of instrument manufacturers acquiring specialized software to streamline diagnostic workflows for labs and pharmaceutical customers.

The $270 million deal includes $240 million at closing and $30 million tied to performance benchmarks, representing a premium over Proscia's $18 million trailing revenue. Proscia currently services more than 4,000 global clinical sites and 16 of the top 20 pharmaceutical companies.

The players

Agilent Technologies

A major manufacturer of analytical instruments, software, and reagents serving the global life sciences and diagnostics sectors.

Proscia

A Philadelphia-based software firm that provides digital pathology platforms for tissue diagnostics and clinical workflows.

The details

Proscia will be integrated into Agilent's Life Sciences and Diagnostics Markets Group, where its digital pathology platform will serve as the software layer for Agilent’s tissue analysis tools. The combination intends to create an end-to-end diagnostic workflow, utilizing Proscia's FDA 510(k)-cleared software to automate and digitize manual lab processes. This operational shift aims to simplify data integration for the thousands of hospitals and clinics currently using Proscia's technology.

September 2022: Companies entered a multiyear distribution agreement.
2026: Proscia named Best in KLAS winner for digital pathology.
Early fiscal 2027: Expected closing of the acquisition.

Market Landscape

This acquisition follows the precedent set by the 2022 distribution agreement between Agilent and Proscia to integrate their respective hardware and software. It marks a transition from a limited partnership to a full consolidation of digital diagnostic software into a large-scale life sciences business.

Operators in clinical diagnostics should prepare for tighter integration between hardware and software vendors, which may limit options for standalone diagnostic tools. Review existing contracts with Agilent or Proscia to determine how the forthcoming transition in 2027 might affect support services or technical interoperability.

The takeaway

The move underscores the growing premium on digital diagnostics software that can integrate directly with existing laboratory hardware. Operators should monitor how Agilent aligns its reagent and instrument pricing strategies with the newly acquired software platform to assess potential shifts in total cost of ownership.